BCL2 and T-cell acute lymphoblastic leukemia: Current research has documented that in T-cell acute lymphoblastic leukemia, FBXW7 deletion results in the upregulation of MCL1, thereby conferring resistance to the BCL2 inhibitor ABT737 [36].